Compare Harley-Davidson Inc (HOG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs TG Therapeutics Inc — how do they compare? Harley-Davidson Inc trades at $26.86 (market cap $2.78B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.9× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.8% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 92 Days and TG Therapeutics Inc for 16 Days on average.
| HOG | TGTX | |
|---|---|---|
Market Cap | $2.78B | $8.16B |
Volume | 2,966,389 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $28.46 | $59.06 |
52-Week Low | $17.19 | $26.94 |
Typical Hold Time | 92 Days | 16 Days |
Enterprise Value | $3.20B | $8.37B |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.90, down 0.19% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings beat ($0.75 vs $0.645 expected) but missed Q1 expectations. Revenue has declined from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 14.86 and P/S of 0.72. Recent news highlights tariff exposure and a data breach investigation.
The stock offers value with reasonable multiples but faces revenue headwinds and operational challenges. Analyst consensus is cautious with 61% hold ratings and $28.50 price target suggesting limited upside. Key risks include declining motorcycle demand, tariff sensitivity, and competitive pressures in the evolving auto industry.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
